Small Molecules, Biologics
Total Trials
68
As Lead Sponsor
61
As Collaborator
7
Total Enrollment
24,550
NCT00691808
Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment
Phase: Phase 2
Role: Lead Sponsor
Start: Feb 29, 2008
Completion: Not specified
NCT00813098
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
Start: Dec 31, 2008
Completion: Aug 31, 2010
NCT00847886
Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis
Phase: Phase 1
Start: Feb 28, 2009
Completion: Mar 31, 2009
NCT00853047
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Start: Mar 31, 2009
Completion: Jun 30, 2014
NCT00903383
Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate
Start: Jul 31, 2009
NCT00962065
Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
Start: Aug 31, 2009
NCT01104415
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
Start: Jun 15, 2010
Completion: Feb 12, 2014
NCT01188863
Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus
Start: Sep 30, 2010
NCT01292993
A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects
Start: Feb 28, 2011
NCT01334242
A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects
Start: Mar 31, 2011
NCT01376557
Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin
Start: Jun 30, 2011
Completion: May 31, 2012
NCT01411800
An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
Start: Aug 31, 2011
NCT01417052
A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis
Start: Sep 30, 2011
Completion: Jun 30, 2012
NCT01441232
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
Start: Oct 31, 2011
NCT01456052
A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
Start: Jan 30, 2012
Completion: Sep 3, 2013
NCT01494233
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
Start: Feb 29, 2012
NCT01528111
Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Phase: Phase 1/2
Start: Mar 31, 2012
NCT01555008
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment
NCT01677910
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Phase: Phase 3
Start: Jan 8, 2013
Completion: Mar 21, 2016
NCT01742208
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
Start: Feb 28, 2013
Completion: Jan 31, 2014
NCT01818232
Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects
Start: Mar 31, 2013
Completion: May 31, 2013
NCT01913002
Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects
Start: Jul 31, 2013
NCT01916850
Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects
Start: Aug 31, 2013
NCT01916863
Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects
NCT01932528
An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
NCT02026063
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Start: Jan 14, 2014
Completion: Sep 12, 2018
NCT02063659
Telotristat Etiprate for Carcinoid Syndrome Therapy
Start: Mar 11, 2014
Completion: Mar 29, 2016
NCT02147808
A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects
Start: May 31, 2014
NCT02155205
A Thorough QT Study of Telotristat Etiprate
NCT02157584
An Open-Label Food Effect Study of Telotristat Etiprate
Start: Jun 30, 2014
NCT02157558
An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
Start: Jul 31, 2014
NCT02195635
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
NCT02300350
DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
Start: Oct 31, 2014
Completion: Dec 31, 2014
NCT02300363
DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
Completion: Nov 30, 2014
NCT02373046
Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets
Start: Feb 28, 2015
NCT02384941
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
Start: Mar 31, 2015
Completion: Feb 28, 2017
NCT02383940
Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
Start: Apr 30, 2015
Completion: Sep 30, 2016
NCT02421510
Start: May 31, 2015
Completion: Jun 23, 2017
NCT02471274
PK Study of Sotagliflozin in Subjects With Hepatic Impairment
Start: Jun 30, 2015
NCT02459899
Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
Start: Jul 31, 2015
Completion: Aug 31, 2016
NCT02494609
Oral Contraceptive DDI Study
NCT02531035
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
Start: Sep 30, 2015
Completion: Apr 30, 2017
NCT02647918
Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function
Start: Dec 31, 2015
Completion: Sep 30, 2017
NCT02926937
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Start: Nov 11, 2016
Completion: May 17, 2019
NCT02926950
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Start: Nov 30, 2016
Completion: Mar 22, 2019
NCT03066830
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
Start: Feb 24, 2017
Completion: Apr 30, 2019
NCT03242018
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Start: Aug 16, 2017
Completion: Dec 11, 2019
NCT03242252
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Completion: Oct 25, 2019
NCT03285594
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Start: Sep 15, 2017
Completion: Sep 27, 2019
NCT03302845
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
Start: Sep 21, 2017
Completion: Nov 7, 2017
NCT03351478
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
Start: Nov 27, 2017
Completion: May 16, 2019
NCT03423446
Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
Start: Nov 28, 2017
Completion: Jun 15, 2018
NCT03332771
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Start: Dec 1, 2017
Completion: Sep 6, 2019
NCT03292653
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
Start: Dec 4, 2017
Completion: Aug 17, 2019
NCT03315143
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
Start: Dec 19, 2017
Completion: Jul 8, 2020
NCT03386344
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Start: Feb 19, 2018
Completion: May 30, 2020
NCT03521934
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Start: Jun 15, 2018
Completion: Jun 5, 2020
NCT03910387
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Role: Collaborator
Start: Apr 17, 2019
Completion: Oct 1, 2024
NCT04455633
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Start: Sep 3, 2020
Completion: Jun 28, 2022
NCT04034745
Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Phase: N/A
Start: Oct 31, 2020
Completion: Nov 30, 2023
NCT04662281
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Start: Dec 29, 2020
Completion: Dec 21, 2022
NCT06203002
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
Start: Nov 29, 2023
Completion: Feb 24, 2025
NCT05696366
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
Start: Sep 9, 2024
Completion: Jan 31, 2028
NCT06481891
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Start: Sep 24, 2024
Completion: Aug 31, 2026
NCT06217302
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Start: Oct 31, 2024
Completion: May 31, 2029
NCT06435156
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
Start: Jan 28, 2025
Completion: Oct 31, 2027
NCT06933056
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
Phase: Early Phase 1
Start: Sep 2, 2025
Completion: Sep 30, 2026
NCT07211802
CKM For Safe Use of SGLT2i in Type 1 Diabetes
Start: Jul 1, 2026
Completion: Dec 31, 2030
Loading map...